$Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease results from a multicentre cohort study /$
QR kód

Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease results from a multicentre cohort study /

Elmentve itt :

Bibliográfiai részletek
Szerzők:	Bacsur Péter Matuz Mária Resál Tamás Miheller Pál Szamosi Tamás Schäfer Eszter Sarlós Patrícia Iliás Ákos Szántó Kata Judit Rutka Mariann Bálint Anita Milassin Ágnes Fábián Anna Bor Renáta Szepes Zoltán Molnár Tamás Farkas Klaudia
Dokumentumtípus:	Cikk
Megjelent:	2022
Sorozat:	THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 15 No. January-December
Tárgyszavak:	Klinikai orvostan
doi:	10.1177/17562848221144349
mtmt:	33532273
Online Access:	http://publicatio.bibl.u-szeged.hu/25882

Leíró adatok
Terjedelem/Fizikai jellemzők:	18 1-18
ISSN:	1756-283X

Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease results from a multicentre cohort study /

Hasonló tételek